These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 12243608)

  • 1. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment option for heart failure patients: eplerenone.
    Southworth MR; Cavallari LH
    J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Struthers A; Krum H; Williams GH
    Clin Cardiol; 2008 Apr; 31(4):153-8. PubMed ID: 18404673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a review of its use in essential hypertension.
    Croom KF; Perry CM
    Am J Cardiovasc Drugs; 2005; 5(1):51-69. PubMed ID: 15631538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.